drugset / Trial / NCT06004037

Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex

NCT06004037

Phase 2 Completed 24 enrolled LigaChem Biosciences, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of delpazolid add-on therapy in Patients with Refractory Mycobacterium abscessus Complex Pulmonary disease

Timeline

Start
2024-01-16
Primary completion
2025-09-15
Completion
2026-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Delpazolid Small molecule 1200 mg Oral